Intermenstrual bleeding


Intermenstrual bleeding, or metrorrhagia, is abnormal vaginal bleeding at irregular intervals between expected menstrual periods. It may be associated with bleeding with sexual intercourse. The term metrorrhagia, in which metro means measure and -rrhagia means abnormal flow, is no longer recommended.
In some women, menstrual spotting between periods occurs as a normal and harmless part of ovulation. Some women experience acute mid-cycle abdominal pain around the time of ovulation. This may also occur at the same time as menstrual spotting.
The term breakthrough bleeding is usually used for women using hormonal contraceptives, such as IUDs or oral contraceptives. It refers to bleeding or spotting between any expected withdrawal bleeding, or at any time if none is expected. If spotting continues beyond the first 3–4 cycles of oral contraceptive use, a woman should have her prescription adjusted to a pill containing higher estrogen:progesterone ratio by either increasing the estrogen dose or decreasing the relative progesterone dose.
Besides the aforementioned physiologic forms, IMB may also represent abnormal uterine bleeding and be a sign of an underlying disorder, such as a hormone imbalance, endometriosis, uterine fibroids, uterine cancer, or vaginal cancer.
If the bleeding is repeated and heavy, it can cause significant iron-deficiency anemia.

Causes

Intermittent spotting between periods can result from any of numerous reproductive system disorders:
Neoplasia:
Inflammation:
Bleeding disorders:
Drug induced:
Traumatic causes:
Related to pregnancy:
Other causes:
Breakthrough bleeding is any of various forms of vaginal bleeding, usually referring to mid-cycle bleeding in users of combined oral contraceptives as attributed to insufficient estrogens. It may also occur with other hormonal contraceptives. Sometimes, breakthrough bleeding is classified as abnormal and thereby as a form of IMB.
In the context of hemophilia, the term describes a bleeding that occurs while a patient is on prophylaxis.

Presentation

The bleeding is usually light, often referred to as "spotting," though a few people may experience heavier bleeding.
It is estimated that breakthrough bleeding affects around 25% of combined oral contraceptive pill users during the initial 3 to 4 months of use, it then usually resolves on its own.

Mechanism

Breakthrough bleeding is commonly due to 4 factors: physiologic effects of OCs on the endometrium, OC-related parameters, , patient behavior, and benign or malignant pathology.

Treatment

Breakthrough bleeding that does not resolve on its own is a common reason for women to switch to different pill formulations, or to switch to a non-hormonal method of birth control.